U.S. Markets open in 8 hrs 7 mins
  • S&P Futures

    4,292.25
    -6.00 (-0.14%)
     
  • Dow Futures

    33,861.00
    -12.00 (-0.04%)
     
  • Nasdaq Futures

    13,660.25
    -21.00 (-0.15%)
     
  • Russell 2000 Futures

    2,022.30
    -1.50 (-0.07%)
     
  • Crude Oil

    88.84
    -0.57 (-0.64%)
     
  • Gold

    1,795.80
    -2.30 (-0.13%)
     
  • Silver

    20.19
    -0.08 (-0.40%)
     
  • EUR/USD

    1.0163
    -0.0002 (-0.0203%)
     
  • 10-Yr Bond

    2.7910
    0.0000 (0.00%)
     
  • Vix

    19.95
    +0.42 (+2.15%)
     
  • GBP/USD

    1.2049
    -0.0009 (-0.0735%)
     
  • USD/JPY

    133.3880
    +0.1160 (+0.0870%)
     
  • BTC-USD

    23,883.97
    -952.80 (-3.84%)
     
  • CMC Crypto 200

    565.56
    -25.20 (-4.27%)
     
  • FTSE 100

    7,509.15
    +8.26 (+0.11%)
     
  • Nikkei 225

    28,878.76
    +6.98 (+0.02%)
     

AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER, British Columbia, February 23, 2022--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will participate in a panel during the Truist Securities AI Symposium – Biotech & Tools. The panel is titled, "Integrated Platforms for AI-based Drug Discovery," and will take place virtually on Tuesday, March 1, 2022, at 8:20 a.m. Pacific Time.

A live audio webcast of the panel may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006146/en/

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Neil Berkley; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116